Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging by unknown
ORIGINAL ARTICLE
Amyloid PET in European and North American cohorts;
and exploring age as a limit to clinical use of amyloid imaging
Konstantinos Chiotis1 & Stephen F. Carter1,2 & Karim Farid1,3 & Irina Savitcheva4 &
Agneta Nordberg1,5 & for the Diagnostic Molecular Imaging (DiMI) network
and the Alzheimer’s Disease Neuroimaging Initiative
Received: 3 January 2015 /Accepted: 10 June 2015 /Published online: 2 July 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract
Purpose Several radiotracers that bind to fibrillar amyloid-
beta in the brain have been developed and used in various
patient cohorts. This study aimed to investigate the compara-
bility of two amyloid positron emission tomography (PET)
tracers as well as examine how age affects the discriminative
properties of amyloid PET imaging.
Methods Fifty-one healthy controls (HCs), 72 patients with
mild cognitive impairment (MCI) and 90 patients with
Alzheimer’s disease (AD) from a European cohort were
scanned with [11C]Pittsburgh compound-B (PIB) and com-
pared with an age-, sex- and disease severity-matched popu-
lation of 51 HC, 72 MCI and 84 AD patients from a North
American cohort who were scanned with [18F]Florbetapir.
An additional North American population of 246 HC, 342
MCI and 138 AD patients with a Florbetapir scan was split
by age (55–75 vs 76–93 y) into groups matched for gender
and disease severity. PET template-based analyses were used
to quantify regional tracer uptake.
Results The mean regional uptake patterns were similar and
strong correlations were found between the two tracers across
the regions of interest in HC (ρ=0.671, p=0.02), amyloid-
positive MCI (ρ=0.902, p<0.001) and AD patients (ρ=
0.853, p<0.001). The application of the Florbetapir cut-off
point resulted in a higher proportion of amyloid-positive HC
and a lower proportion of amyloid-positive AD patients in the
older group (28 and 30 %, respectively) than in the younger
group (19 and 20 %, respectively).
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Conclusions These results illustrate the comparability of
Florbetapir and PIB in unrelated but matched patient popula-
tions. The role of amyloid PET imaging becomes increasingly
important with increasing age in the diagnostic assessment of
clinically impaired patients.
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Introduction
Alzheimer’s disease (AD) pathology is characterised by the
accumulation of amyloid-beta (Aβ) plaques, neurofibrillary
tangles and neuronal degeneration [1, 2]. The use of positron
emission tomography (PET) with amyloid-specific radio-
tracers has enabled in vivo imaging of fibrillar Aβ plaques;
[11C]Pittsburgh compound-B (PIB) was the first generation
of these tracers [3]. The short half-life of [11C] (~20 min) led
to the development of [18F] derivatives (half-life ~110 min)
[4]. The longer half-life of [18F] negates the need for on-site
cyclotron and radiochemistry facilities, as [18 F] tracers can be
produced centrally and delivered to geographically dispersed
sites, thus enabling their clinical use. [18F]Florbetapir
(Florbetapir) was the first [18 F] radiotracer specific for Aβ
to receive approval from both the U.S. Food and Drug Ad-
ministration (FDA) (2012) and the European Medicines
Agency (2013) for assessing the presence of Aβ pathology
in individuals with cognitive decline. These advances in mo-
lecular imaging led to a proposed revision of the diagnostic
criteria for AD, in which amyloid PET plays an important role
[5].
Autopsy studies of individuals who were scanned prior to
death using PIB or Florbetapir have confirmed that both ra-
diotracers bind selectively to fibrillar Aβ [6–9]. Moreover,
in vivo studies have demonstrated the comparability of these
two amyloid radiotracers within the same patient population
[10–12]; however, it is uncertain how comparable PIB and
Florbetapir are between different populations.
The ages of individuals who present to a memory clinic
with cognitive deficits typically span a wide continuum and
it is not yet completely clear what impact age has on the
discriminative ability of amyloid imaging. It has been demon-
strated that cognitively normal adults aged >60 years can pos-
sess pathological brain levels of fibrillar Aβ (i.e. they are
amyloid positive) [13–19]. The number of amyloid-positive,
cognitively normal individuals increases with age from ~6 %
of those aged between 55 and 60 years to >30 % of those aged
80 years or more [17]. It is imperative to understand whether
these individuals are in a high-risk pre-AD state or are
experiencing normal age-related brain changes. Additionally,
much uncertainty still exists about the relative Aβ loads of AD
patients in different age groups.Most research arbitrarily splits
patients into two subtypes based on a cut-off point at 65 years
of age, namely early-onset and late-onset AD (EoAD and
LoAD, respectively). Several post mortem studies have dem-
onstrated significantly greater Aβ burden in patients with
EoAD than in those with LoAD [20–22], but PETstudies have
failed to give consistent results [23–25]. It is clear that under-
standing the impact of age on amyloid PET results is an im-
portant issue, regardless of whether individuals present at an
asymptomatic or advanced disease state.
The purpose of this investigation was, therefore, twofold:
1) to validate cross-radiotracer comparisons (PIB vs
Florbetapir) in unrelated but matched patient populations
and determine the comparability of amyloid PET data; and
2) to examine the distribution of amyloid-positive brain scans
in different age groups, establish how age affects the discrim-
inative power of amyloid PET imaging in those of advanced
age (where >30 % of cognitively normal adults can be amy-
loid positive) and establish whether apolipoprotein ε4
(ApoE4) differentially mediates the Aβ load in AD patients
at different ages. To achieve these goals, data were used from
two well-characterised data sets that have both clinical and
amyloid PET data available. PIB data were obtained from
the Diagnostic Molecular Imaging (DiMI) consortium and
Florbetapir data were downloaded from the Alzheimer’s Dis-
ease Neuroimaging Initiative (ADNI) site.
Materials & methods
DiMI consortium
Some of the data used in the preparation of this article were
obtained from the European Network of Excellence on DiMI,
which was funded by the European Union (EC-FP6),
launched in 2005 and ended in 2010. The goal of the DiMI
consortium, which comprised six groups from five European
countries, was to retrospectively collect PET data from five
European centres in order to determine the role of amyloid
imaging (using PIB as tracer) in a large population of mild
cognitive impairment (MCI) and AD patients [26].
ADNI
The remaining data used in the preparation of this article were
obtained from the ADNI database (adni.loni.usc.edu). The
ADNI was launched in 2003 by the National Institute on Ag-
ing (NIA), the National Institute of Biomedical Imaging and
Bioengineering (NIBIB), the FDA, private pharmaceutical
companies and non-profit organisations, as a $60 million, 5-
year public-private partnership. The primary goal of ADNI
has been to test whether serial magnetic resonance imaging
(MRI), PET, other biological markers, and clinical and neuro-
psychological assessment can be combined to measure the
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progression of MCI and early AD. Determination of sensitive
and specific markers of very early AD progression is intended
to aid researchers and clinicians to develop new treatments
and monitor their effectiveness, as well as lessen the time
and cost of clinical trials.
The principal investigator in this initiative is Michael W.
Weiner, MD (VAMedical Center and University of California
– San Francisco). ADNI is the result of the efforts of many co-
investigators from a broad range of academic institutions and
private corporations, and individuals have been recruited from
over 50 sites across the USA and Canada. The initial goal of
the ADNI was to recruit 800 individuals but ADNI has been
followed by ADNI-GO and ADNI-2. To date these three pro-
tocols have recruited over 1500 adults, ages 55 to 90, to par-
ticipate in the research, consisting of cognitively normal older
individuals, people with early or late MCI, and people with
early AD. The follow-up duration of each group is specified in
the protocols for ADNI-1, ADNI-2 and ADNI-GO. Individ-
uals originally recruited for ADNI-1 and ADNI-GO had the
option to be followed in ADNI-2. For up-to-date information,
see www.adni-info.org.
Study population
Data included in this study were derived from two patient
cohorts, as follows.
DiMI cohort – [11C]PIB
Data were collected from a population comprising 51 healthy
controls (HCs), 72 MCI patients and 90 AD patients from the
DiMI PIB consortium [26]. The AD patients fulfilled the
NINCDS-ADRDA criteria for probable AD [27] and the
DSM-IV criteria for dementia of AD type [28], whereas the
MCI patients fulfilled the Petersen criteria [29]. The patients
were recruited from five European research centres for AD
(Technische Universität München, Munich, Germany;
Katolieke Universiteit Leuven, Leuven, Belgium; Imperial
College London, London, UK; Karolinska Institutet, Stock-
holm, Sweden; and Turku PET Centre, University of Turku,
Finland) and completed at least one PIB scanning session.
More details can be found in Nordberg et al. [26]. Data re-
garding the education and ApoE4 status of the participants are
reported in Table 1.
ADNI cohort – [18F] Florbetapir
Data for a population of 916 individuals who had had at least
one Florbetapir scan were downloaded from the ADNI data-
base. The AD patients fulfilled the NINCDS-ADRDA criteria
[27] whereas the MCI patients had a clinical dementia rating
of 0.5, abnormal memory function as documented on the Log-
ical Memory II subscale, and were not demented [30]. After
exclusion of 11 individuals without MRI scans or with poor-
quality Florbetapir scans, we composed two groups from the
remaining participants. First, age, mini-mental state examina-
tion (MMSE) score and gender distribution were randomly
matched in a relatively young group of 51 HC, 72 MCI and
84 AD patients to the participants of the DiMI cohort. Second,
the total ADNI population was split into younger (aged 55-
75 y) and older (aged 76-83 y) subgroups. Randomised
matching of these subgroups for MMSE score and gender
distribution (HC, and MCI or AD patients) resulted in 363
individuals in each age subgroup. 159 individuals from the
ADNI database appeared in both analyses. From the total of




All of the PIB data were processed in accordance with the
methodology outlined in Nordberg et al. [26]; PIB data were
summed between 40 and 60 min after injection of the tracer
for each of the 213 participants. All available PET data sets
(n=213) were non-linearly spatially normalised to a
population-specific PIB-PET template based on the mean
PIB data from the 151 individuals who had MRI data avail-
able. A binarised grey matter (GM) anatomical mask was
generated and multiplied by a standard digital atlas [31] to
create 12 bilateral anatomically defined GM regions of interest
(ROI) (temporal lobe, frontal lobe, occipital lobe, parietal
lobe, insular lobe, anterior cingulate, posterior cingulate, cau-
date nucleus, putamen, thalamus, hippocampus, and
parahippocampal gyrus) in Montreal Neurological Institute
(MNI) space. A cerebellar GM region was used as reference
for each 40–60 min PIB image in order to create standardized
uptake value ratio (SUVR) images for each individual (based
on the median cerebellar uptake). A composite neocortical
ratio (CCTXR) was calculated for each individual, resulting
in a weighted average for the frontal, parietal and basal/lateral
temporal regions. More details regarding the applied method-
ology can be found in the original publication [26].
[18 F]Florbetapir
Raw Florbetapir frames acquired between 50 and 70 min after
injection of the tracer were downloaded from the ADNI data-
base and summed. The 207 Florbetapir images used in the
comparison with PIB data had an accompanying MRI image
that was used for the spatial normalisation of the respective
integral co-registered PET images to MNI space, similarly to
the method used for the PIB data. An average Florbetapir
image was generated from these 207 images and used as a
sample-based Florbetapir-PET template in MNI space. All
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raw Florbetapir images used in this project (n=774) were
subsequently spatially normalised to MNI space with the use
of this template. A whole cerebellum region (based on the
mean cerebellar uptake) was used as a reference for all 50-
70 min Florbetapir images as it displayed lower variance of
the HCs and larger effect size between HC and AD patients in
comparison to the cerebellar GM region (Supplementary
Table 1). The same anatomical mask as that used for the PIB
data was applied to the Florbetapir data in order to define GM
ROIs on the standard digital atlas, resulting in the same 12
bilateral GM ROIs as well as a CCTXR, as described above.
The pre-processing of the images (i.e., segmentation, co-
registration as well as spatial normalisation steps) for both
tracers was performed using SPM5 (Functional Imaging Lab-
oratory, Wellcome Department of Imaging Neuroscience,
UCL, London).
Visual assessment of [18 F]Flurodeoxyglucose (FDG)
scans
The ADNI database FDG-PET (30–60 min) images from the
AD patients in both age groups whose Florbetapir scans were
negative for amyloid using the quantitative method, according
to the cut-off point described below, were visually assessed for
the presence of an AD-like pattern of hypometabolism [32] by
two independent, experienced nuclear medicine specialists
(raters) who were blinded to the clinical and demographic
backgrounds of the individuals.
Statistical methods
Differences between the groupswere assessedwith analysis of
variance (ANOVA) and chi-squared tests. Two-way ANOVA
was performed in order to evaluate the influence of the factors,
age group and ApoE4 carrier status, on regional Florbetapir
uptake. Two levels for age group (55–75 and 76–83 y
subgroups) and two for ApoE4 status (ApoE4 carriers and
non-carriers) were set. Correlations were examined with the
Spearman rank correlation coefficient (ρ). Receiver operating
characteristic (ROC) analysis between HC and AD patients
was used to identify the points on the curve closest to (0, 1), as
optimum cut-off points. Sensitivity and specificity were cal-
culated. Cohen’s kappa (κ) [33] and Cohen’s d [34] were
calculated. The expectation-maximisation algorithm for mix-
ture models was used to identify the underlying parameters of
the studied sample and to cluster the individuals into subpop-
ulations according to their probability distributions within the
overall population [35].
All statistical analyses and graphical representations were
carried out using SPSS 22.0 for Mac OS X, except for the
mixture model analysis, which was carried out in XLSTAT
2014.2.03 for Microsoft Excel for Mac 2011.
Results
Comparison between PIB and Florbetapir
Demographics
The HC, MCI and AD patients from both cohorts were
matched with regard to their age, gender and general cognitive
status (MMSE). There were no differences in distribution of
the ApoE4 allele between the two cohorts across the different
diagnostic groups. The individuals from the ADNI cohort
were significantly more educated than those from the DiMI
cohort (Table 1).
Uptake characteristics
Florbetapir exhibited higher non-specific white matter (WM)
relative to GM uptake compared to PIB in the visual
Table 1 Demographics for the between-population (DiMI vs ADNI), cross-radiotracer ([11C]PIB vs [18F]Florbetapir) comparison
DiMI ([11C]PIB) (n=213) ADNI ([18F]Florbetapir) (n=207)
HC MCI AD HC MCI AD
n 51 72 90 51 72 84
Age (years) 67.4±6.3 67.5±8.1 69.9±8.2 70.6±3.1 71.8±2.3 69.0±5.3
Gender (m/f) 22/29 37/35 42/48 22/29 37/35 42/42
Education data available, n (mean years±SDa) 27 (13.2±2.2) 42 (12.9±3.2) 69 (12.0±3.1) 51 (16.8±2.7) 72 (16.1±2.6) 84 (15.8±2.6)
ApoE4 status available, n (E4 non-carriers, carriers) 31 (21, 10) 59 (25, 34) 80 (21, 59) 51 (36, 15) 70 (36, 34) 84 (18, 66)
MMSE data available, n (mean score±SD) 43 (29.2±1.1) 72 (27.1±2.0) 90 (23.8±3.1) 51 (29.2±0.9) 72 (27.5±1.8) 84 (23.1±2.3)
Amyloid positive, n (%) 5 (10) 46 (64) 82 (91) 9 (18) 31 (43) 71 (85)
Amyloid positivity has been defined as a composite neocortical ratio (CCTXR) value above the cut-off point of 1.42 for [11C]PIB and 1.34 for
[18F]Florbetapir. (AD: Alzheimer’s disease; SD: standard deviation)
a The years of education for the individuals scanned with [11C]PIB were significantly fewer than the years of the education for the individuals scanned
with [18 F]Florbetapir in the HC (p<0.001), MCI (p<0.001) and AD (p<0.001) groups
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inspection of the scans (Fig. 1). The range of CCTXR values
were lower and narrower for Florbetapir (0.99–2.07) than for
PIB (1.09–2.67) (Fig. 2).
Discriminative ability
Florbetapir was less able than PIB to discriminate between
HC and AD patients according to the ROC analysis of the
CCTXR area under the curve (AUC) values (AUC=0.864
for Florbetapir [95 % confidence interval (CI): 0.798–
0.930] and AUC=0.931 for PIB [95 % CI: 0.888–
0.974]). Consequently, the optimum cut-off point for the
Florbetapir data displayed lower sensitivity as well as
specificity (1.34, 85 and 82 %, respectively) in comparison
to the cut-off point established for PIB (1.42, 91 and 90 %,
respectively). The number of amyloid-positive individuals
(using these cut-off points) from each disease group is
shown in Table 1.
Among the individual ROIs that were included in the
analysis, discrimination between HC and AD patients was
best for both PIB and Florbetapir in the putamen
(Table 2).
Uptake of PIB and Florbetapir is highly correlated
The MCI group was split into amyloid-negative and
amyloid-positive individuals with respect to the above
cut-off points for PIB and Florbetapir. The mean SUVR
values for the investigated ROIs in the respective diagnos-
tic groups (HC/MCI amyloid-negative/MCI amyloid-posi-
tive/AD) followed the same pattern for both tracers (Fig. 3;
Supplementary Table 2). The mean regional SUVR values
for PIB and Florbetapir across the ROIs examined (n=12)
were significantly correlated in the HC (ρ=0.671, p=0.02,
R2=0.795), MCI amyloid-positive patient (ρ=0.902,
p<0.001, R2=0.738) and AD patient (ρ=0.853, p<0.001,
R2=0.778) groups, but not in the MCI amyloid-negative
patient groups although a clear trend was observed (ρ=
0.531, p=0.08, R2=0.782) (Fig. 4a).
Among the disease groups that had a correlation between
the two tracers, the HC group had the highest coefficient of
determination (R2=0.795). Therefore, with the use of the lin-
ear equation derived from the above correlation (y=1.13x–
0.28), the PIB CCTXR cut-off point (1.42) corresponded to
a Florbetapir cut-off point of 1.32 (Fig. 4b).
Comparison of Florbetapir uptake in different age groups
(ADNI data)
Demographics
The HC, MCI and AD patients from both age groups were
matched for gender and general cognitive status (MMSE). The
distribution of the ApoE4 allele differed between the two age
groups for the MCI and AD patients but not for the HCs; the
younger MCI and AD patients were more likely than the older
patients in these groups to be ApoE4 carriers. Moreover, the
younger MCI group was significantly more educated than the
older group (Table 3).
Discriminative ability
The application of the Florbetapir cut-off point (1.34) to the
two age groups resulted in a higher proportion of amyloid-
positive HCs and a lower proportion of amyloid-positive AD
patients in the older group than in the younger one. Amyloid
Fig. 1 Typical examples of
individual SUVR images from
HC, and MCI amyloid-negative
(MCI-), MCI amyloid-positive
(MCI+) and AD patients matched
for age, gender and MMSE.
[11C]PIB scans are on the left and
[18F]Florbetapir scans are on the
right. Amyloid positivity has been
defined as a CCTXR value above
the cut-off points of 1.42 for
[11C]PIB and 1.34 for
[18F]Florbetapir
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positivity occurred to a similar extent in MCI patients in the
two age groups (Table 3). Therefore, the sensitivity and spec-
ificity of Florbetapir in discriminating between HC and AD
patients were poorer in the older ADNI group (72 and 70 %,
respectively) than in the younger group (81 and 80 %,
respectively).
Amyloid-negative AD patients
The amyloid-negative AD patients (n=32) were less likely to
be ApoE4 carriers relative to the amyloid-positive patients
(n=12 [38 %] vs n=79 [79 %], p<0.001). No difference
was observed between the two groups with respect to MMSE
or years of education.
In the visual assessment of the FDG-PET scans in the
amyloid-negative AD patient group the hypometabolism
was regionally diffuse. The agreement between the raters
was poor and not significant (41 %) with both raters con-
sistently assessing nine individuals (28 %) of the amyloid-
negative AD patient group as positive for an AD-like
pattern of hypometabolism in their FDG scans. No differ-
ence was observed between the young and the old
subgroups.
Fig. 2 Histogram representing
the CCTXR values in HC, MCI
and AD patients for [11C]PIB and
[18F]Florbetapir. The dotted line
in each plot represents the
calculated [11C]PIB and
[18F]Florbetapir cut-off points
(1.42 and 1.34, respectively)
Table 2 The abilities of [11C]PIB and [18 F]Florbetapir to discriminate
between HC and patients with AD for all the included ROIs, as assessed
by ROC analysis of the CCTXR AUC values
Discriminative ability
ROIs [11C]PIB [18F]Florbetapir
Putamen 0.966 [0.941–0.990] 0.928 [0.880–0.976]
ACC 0.933 [0.891–0.975] 0.847 [0.780–0.915] ↓6
Parietal 0.932 [0.889–0.975] 0.859 [0.794–0.925] ↓5
PCC 0.929 [0.887–0.971] 0.882 [0.821–0.943] ↑2
Frontal 0.925 [0.881–0.970] 0.835 [0.762–0.907] ↓7
Temporal 0.924 [0.877–0.971] 0.875 [0.812–0.939] ↑3
Occipital 0.915 [0.867–0.964] 0.871 [0.810–0.931] ↑4
Insula 0.908 [0.856–0.959] 0.772 [0.691–0.852]
Caudate Nucleus 0.863 [0.799–0.926] 0.693 [0.606–0.781]
Parahippocampal gyrus 0.834 [0.768–0.899] 0.617 [0.522–0.711]
Thalamus 0.730 [0.648–0.812] 0.415 [0.319–0.511] ↓12
Hippocampus 0.553 [0.459–0.647] 0.483 [0.386–0.580] ↑11
The results are presented as ROC AUC values [95 % confidence inter-
vals] and the ROIs are ranked in descending order according to the rele-
vant discriminative ability of [11C]PIB. Arrows in the [18F]Florbetapir
column represent the difference in ranking from [11C]PIB. (ACC anterior
cingulate cortex; PCC posterior cingulate cortex)
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Fig. 3 Means±SDs of tracers’ SUVR values for the investigated ROIs in
the respective diagnostic groups; HC, andMCI amyloid-negative (MCI-),
MCI amyloid-positive (MCI+) and AD patients. Amyloid positivity has
been defined as a CCTXR value above the cut-off points of 1.42 for
[11C]PIB and 1.34 for [18F]Florbetapir. The data represented graphically
here are tabulated (means ±SDs) in Supplementary Table 2.
([18F]Florbetapir = coral; [11C]PIB = turquoise)
Fig. 4 Scatterplots representing the mean uptake ratios (SUVRs) of each
ROI for [11C]PIB versus [18F]Florbetapir in the respective groups; (a)
HC (amyloid-positive and amyloid-negative individuals), and MCI
amyloid-negative (MCI-), MCI amyloid-positive (MCI+) and AD
patients; and (b) the same graph individually for the HC group
(amyloid-positive and amyloid-negative individuals). The linear
equation derived from the correlation in the HC group (b) was used to
convert the [11C]PIB cut-off point (1.42) to a [18F]Florbetapir cut-off point
(1.32). Amyloid positivity was defined as a CCTXRvalue above the cut-off
points of 1.42 for [11C]PIB and 1.34 for [18F]Florbetapir. Every data
point represents the mean value for a bilateral ROI and not an individual
participant. †: Caudate nucleus; ¥: Occipital cortex
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Florbetapir uptake in the different diagnostic groups
Healthy controls
Two-way ANOVA indicated that older age, independent of
ApoE4 status, had a significant positive effect on amyloid
deposition only in the putamen (F1,240=14.34, p<0.001) and
a negative effect in the thalamus (F1,240=5.10, p=0.025) in
HCs. The presence of the ApoE4 allele had an independent,
significant, positive effect on amyloid deposition in every ROI
examined except the hippocampus and parahippocampal gy-
rus (Table 4). No statistically significant interaction was ob-
served between age group and ApoE4 carrier status in any of
the ROIs examined.
Table 3 Demographics for the within-population (ADNI) age comparison
Younger ADNI group (55-75 y, n=363) Older ADNI group (76-93 y, n=363)
HC MCI AD HC MCI AD
n 123 171 69 123 171 69
Age (years)a 70.6±3.1 71.8±2.3 69.0±5.3 81.0±4.0 80.7±3.7 81.4±4.0
Gender (m/f) 55/68 105/66 35/34 66/57 106/65 45/24
Education data available, n (years±SD) 123 (16.3±2.7) 171 (16.3±2.7b) 69 (15.9±2.6) 123 (16.4±2.8) 171 (15.6±2.9b) 69 (15.7±2.8)
ApoE status available, n (E4 non-carriers, carriers) 121 (84, 37) 170 (81, 89)c 67 (14, 53)d 123 (95, 28) 169 (106, 63)c 65 (27, 38)d
MMSE data available, n (mean score±SD) 123 (29.1±1.1) 171 (27.9±1.8) 69 (22.6±3.4) 123 (29.0±1.2) 171 (27.7±1.7) 69 (22.3±2.7)
Amyloid Positive, n (%) 24 (20) 83 (49) 56 (81) 37 (30) 91 (53) 50 (72)
Amyloid positivity has been defined as a CCTXR value above the cut-off point of 1.34 for [18F]Florbetapir. (AD Alzheimer’s disease; SD standard
deviation)
a The mean ages of the two age groups differed significantly for each diagnostic group (p<0.001)
b The younger MCI patients were significantly more educated than the older MCI patients (p=0.029)
c The younger MCI patient group had significantly more ApoE4 carriers than the older MCI group (p=0.005)
d The younger AD patient group had significantly more ApoE4 carriers than the older AD group (p=0.010)
Table 4 The independent effects of age and ApoE4 carrier status on the [18 F]Florbetapir uptake ratio for the examined ROI (two-way ANOVA
analysis)










CCTXR 1.26±0.12 1.26±0.17 0.646 <0.001 1.48±0.17 1.39±0.21 0.036 <0.001
Frontal 1.27±0.13 1.25±0.18 0.755 0.001 1.48±0.18 1.38±0.22 0.040 <0.001
Temporal 1.26±0.11 1.27±0.15 0.196 <0.001 1.48±0.16 1.41±0.20 0.069 <0.001
Parietal 1.26±0.13 1.25±0.17 0.967 0.001 1.49±0.18 1.40±0.21 0.029 <0.001
Occipital 1.31±0.10 1.32±0.13 0.355 0.020 1.49±0.16 1.46±0.17 0.255 0.005
ACC 1.22±0.18 1.21±0.23 0.626 <0.001 1.53±0.25 1.39±0.27 0.028 <0.001
PCC 1.26±0.18 1.29±0.23 0.155 <0.001 1.62±0.25 1.51±0.28 0.041 <0.001
Insula 1.15±0.12 1.13±0.17 0.992 0.002 1.35±0.20 1.22±0.21 0.005 <0.001
Caudate nucleus 0.83±0.17 0.79±0.21 0.338 <0.001 1.00±0.25 0.87±0.30 0.075 0.017
Putamen 1.17±0.14 1.23±0.17 <0.001 <0.001 1.57±0.23 1.53±0.24 0.832 <0.001
Thalamus 0.94±0.12 0.88±0.15 0.025 <0.001 0.92±0.19 0.82±0.16 0.032 0.157
Parahippocampal gyrus 1.09±0.08 1.09±0.10 0.433 0.055 1.15±0.13 1.10±0.13 0.054 0.031
Hippocampus 1.08±0.08 1.06±0.10 0.259 0.725 1.07±0.12 0.99±0.16 0.004 0.311
ApoE4 carriers, n (%) 37 (31) 28 (23) 53 (79)c 38 (58)c
ACC anterior cingulate cortex; PCC posterior cingulate cortex
a Independent effects of age on the amyloid load in the ROIs after inclusion of ApoE4 status
b Independent effects of ApoE4 status on the amyloid load in the ROIs after inclusion of age group
c Significantly more younger than older Alzheimer’s disease patients were ApoE4 carriers (p=0.010)
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The Kolmogorov-Smirnov test revealed that the distribu-
tion of the CCTXR results in younger HCs differed signifi-
cantly from a normal distribution pattern (p=0.002), whereas
the distribution in older HCs was more likely to follow a
normal distribution pattern (p=0.083). Mixture model analy-
sis found that the CCTXR values for the younger HCs were
more likely to be a mixture of two components with mean
values of 1.23±0.08 (n=110) and 1.52±0.08 (n=13),
representing relatively low and high amyloid deposition, re-
spectively. The values for the older HCs were more likely to
follow a single normal distribution, with a mean value of 1.26
±0.16 (n=123) (Fig. 5a). There were no differences between
the younger HCs in the higher and lower amyloid deposition
groups with respect to MMSE, years of education, age or
gender distribution. However, the younger HCs in the higher
amyloid deposition group were more likely to be ApoE4 car-
riers than those in the lower amyloid deposition group (n=9
[69 %] vs n=28 [26 %], p=0.001).
AD patients
In AD patients, two-way ANOVA analysis indicated a signifi-
cant negative effect of older age, independent of the presence of
the ApoE4 allele, on the levels of amyloid deposition in diffuse
cortical and subcortical ROIs: CCTXR (F1,128=4.47, p=0.036),
frontal (F1,128=4.29, p=0.040), parietal cortex (F1,128=4.89,
p=0.029), anterior cingulate (F1,128=4.96, p=0.028), posterior
cingulate (F1,128=4.28, p=0.041), insular cortex (F1,128=8.20,
p=0.005), thalamus (F1,128=4.71, p=0.032) and hippocampus
(F1,128=8.46, p=0.004). The independent, positive effect of the
ApoE4 allele on amyloid distribution was significant in every
ROI examined except the thalamus and the hippocampus
(Table 4). No statistically significant interaction was observed
between age group and ApoE4 carrier status in any of the ROIs
examined except the thalamus (F1,128=4.74, p=0.035); the
presence of the ApoE4 allele increased the amyloid levels in
younger AD patients but not in the older group.
Fig. 5 Density plots of the
[18F]Florbetapir CCTXR values
of younger (y; 55–75 y) and older
(o; 76–93 y) age groups in (a)
HCs, (b) MCI patients and (c) AD
patients. Mixture model analysis
using the expectation-
maximisation algorithm allowed
investigation of the possible
underlying components of the
distributions. The dotted line in
each plot represents the calculated
[18F]Florbetapir cut-off point
(1.34)
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The Kolmogorov-Smirnov test revealed that the distribu-
tion of the CCTXR results in younger AD patients was more
likely to follow a normal distribution pattern (p=0.200)
whereas the values for the older AD patients differed signifi-
cantly from a normal distribution pattern (p=0.007). Mixture
model analysis showed that the CCTXR values for the youn-
ger AD patients were more likely to follow a single normal
distribution, with a mean value of 1.48±0.17 (n=69). The
values for the older AD patients were more likely to follow
a mixed distribution containing two components with mean
values of 1.08±0.13 (n=15) and 1.48±0.13 (n=54),
representing relatively low and high amyloid deposition
levels, respectively (Fig. 5c). There were no differences be-
tween the higher and lower amyloid deposition groups in the
older AD patients with respect to MMSE, age or gender dis-
tribution. However, the older AD patients in the lower amy-
loid deposition group were less likely to be ApoE4 carriers
(n=1 [7 %] vs n=37 [74 %], p<0.001) and more likely to be
highly educated (17.1±2.5 vs 15.4±2.8 y, p=0.036) than
those in the higher amyloid deposition group.
Two-way ANOVA analysis of the younger AD patients in
comparison to the older AD patients with high amyloid depo-
sition, indicated a significant positive effect of older age, in-
dependent of the presence of the ApoE4 allele, on the levels of
amyloid deposition only in the putamen (F1,101=4.61, p=
0.034).
MCI patients
Two-way ANOVA analysis indicated a significant positive
effect of older age, independent of the presence of the ApoE4
allele, on the levels of amyloid deposition in the posterior
cingulate (F1,335=4.31, p=0.039), and the putamen (F1,335=
5.78, p=0.017). The independent positive effect of the ApoE4
allele on amyloid distribution was significant in every ROI
examined (Supplementary Table 3).
The Kolmogorov-Smirnov test revealed that the amyloid
distributions for both younger and older MCI patients did not
differ significantly from a normal distribution pattern (p=
0.068 and p=0.200, respectively). Mixture model analysis
confirmed that the distributions of both younger and older
MCI patients were more likely to follow a single normal dis-
tribution, with mean values of 1.36±0.19 (n=171) for youn-
ger MCI patients and 1.35±0.20 (n=171) for older MCI pa-
tients (Fig. 5b).
Discussion
Although the recently developed [18F] amyloid-PET tracers
bind to the same high affinity site as PIB [36], further inves-
tigation was required into the comparability of the tracers and
the extent of inter- and intra-cohort variation in the relevant
cohorts.
The first aim of this study was to compare two age- and
sex-matched populations, which were unrelated, geographi-
cally distinct and scanned with different amyloid tracers
(PIB in the DiMI cohort and Florbetapir in the ADNI cohort).
This study illustrates the high agreement of regional uptake
as well as correlation between the two tracers across the dif-
ferent ROIs examined in every diagnostic group, although
different individuals were scanned with each tracer. The lack
of a clear correlation, however, in the MCI amyloid-negative
group probably reflects the extensive heterogeneity of the pa-
thology in that specific group.
Despite the significant correlation, Florbetapir performed
less well at discriminating between HC and AD patients than
PIB. Florbetapir binds less than PIB to fibrillar Aβ in GM and
has relatively more non-specific WM uptake on visual inspec-
tion, as previously reported by Wolk et al. [12]. Data from
Landau et al. [11] also supports this, in that PIB displayed
higher GM uptake than Florbetapir, although the two tracers
exhibited comparable WM uptake. Florbetapir is also known,
from animal studies, to have lipophilic metabolites that can
cross the blood–brain barrier and increase the non-specific
background signal in amyloid PET [37], in comparison to
PIB [3]. These factors fit with the current Florbetapir data in
our study, since the GM range for Florbetapir uptake was
much narrower than that for PIB. Moreover, the difference
in the range of the two tracers becomes especially apparent
in high SUVR values, where PIB displays a much wider range
in comparison to Florbetapir, whereas in low SUVR values
the ranges of the two tracers are similar (Fig. 2). This differ-
ence in range has probably led to a steeper slope of the corre-
lation between tracers in the AD and MCI amyloid-positive
groups in comparison to the HC and MCI amyloid-negative
groups.
As discussed above, the relatively higher non-specific
WM uptake (and metabolites) of Florbetapir and, therefore,
the greater spill over from WM into GM in comparison to
PIB could have affected the effect size between HC and AD
patients, despite the observed correlation. In the current
study, no partial volume correction was applied to either
the PIB or Florbetapir data in order to further illustrate
the robust comparability between the two tracers regardless
of their different characteristics. Nonetheless, in order to
account for the spill over of non-specific WM binding to
GM with Florbetapir we investigated the use of different
reference regions, as the cerebellar GM reference used for
the PIB data was sub-optimum for the Florbetapir data. A
reference region containing partly WM (whole cerebellum)
at least partly cancelled out the spill over from the highly
variable non-specific WM binding of Florbetapir, resulting
in reduced variability in the HC group and an increase in
the effect size between HC and AD patients.
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Neocortical cut-off points for amyloid positivity were de-
fined in order to examine the sensitivity and specificity of each
tracer. The CCTXR cut-off point (1.42) and sensitivity/
specificity established here for PIB were comparable to values
in the literature [16, 26, 38, 39]. Conversely, the cut-off point
for Florbetapir (1.34) was higher than the range of previously
published values (1.08–1.30) [17, 40–42], although it was
very close to the cut-off of the study that used a methodology
similar to the current one (1.30) [41]. However, despite the
difference in the absolute cut-off value, Florbetapir detected
similar percentages of amyloid-positive HC and AD patients
in a similar relatively young age group [17]. Moreover, use of
the linear correlation between the two tracers in the HC group
allowed us to show that the CCTXR cut-off point for PIB
(1.42) could be converted to a Florbetapir cut-off point
(1.32) with high agreement to the value derived from the in-
dependent ROC analysis of the Florbetapir data (1.34). Inter-
estingly, we observed that although the cut-off value did not
change significantly, there was a difference in the discrimina-
tive abilities of the two Florbetapir cut-off points (89/76 and
85/82, respectively), probably due to the smaller range of the
Florbetapir values.
The large variance in the published cut-off points poses
questions regarding the use of amyloid PET cut-offs in a clin-
ical setting. Cut-off points are known to be sensitive to the
specific tracer for which they were generated and the method-
ology implemented, further limiting the wide use of a single
value. However because of the inherent problems with cut-off
values, there have been recent efforts to standardise quantita-
tive amyloid imaging measures on a centiloid scale (0–100)
for all amyloid tracers ([11C] and [18 F]). Such
standardisation will enable different researchers using differ-
ent amyloid PET tracers to compare their data more easily
[43], particularly when measuring treatment effects in clinical
trials. Nonetheless, the combination of different amyloid PET
tracers on the same scale has important caveats that are illus-
trated in this study. Although the tracers studied are compara-
ble, their different inherent characteristics (non-specific WM
binding, range of GM values, discriminative ability of the two
tracers) limit their interchangeable use. Moreover, according
to the original centiloid paper [43], calibrating the values of
different tracers onto a common scale is not lacking other
limitations. As it is illustrated in that study, at least 25 individ-
uals should have been scanned with both PIB as well as the
other amyloid-specific tracers in an interval of less than
3 months in order for each centre to convert the values of
the latter tracers into centiloids. Very few centres worldwide
have such complimentary amyloid PET data. Although one of
the goals of the centiloid project is to encourage centres that do
have the data to make the scaling conversions possible from
Bnon-standard^ tracers available for all, the data for the non-
standard scaling conversions are, as yet, unavailable to the
wider PET community.
The best discrimination between HC and AD patients
among the investigated ROIs in our study was observed in
the putamen. It is already known from presenilin-1 mutation
carriers that Aβ deposition in the striatum is an early phenom-
enon in the progression of autosomal-dominant AD [44].
However, it is believed that Aβ accumulates in the striatum
relatively late in the course of sporadic AD pathology [2, 45].
Our findings are supported by autopsy studies in which the
presence of moderately frequent/frequent striatal plaques in
the putamen was used to differentiate between the presence
and absence of clinicopathological AD with a sensitivity and
specificity above 85 % [46] and by a machine-learning amy-
loid PET study where the voxels with the highest feature
weights for classification between HC and AD patients were
located in the striatum [47]. Therefore, clinical assessment of
subcortical structures for the presence of Aβ pathology could
be of great importance in early AD diagnosis.
The difference between the two geographically distinct re-
cruitment cohorts (North American and European) in the total
years of education exceeded 3 years in every disease group.
The average educational attainment of the individuals in the
North American cohort (ADNI) was high, equivalent to uni-
versity graduate, whereas the average participant in the Euro-
pean cohort (DiMI) was equivalent to high-school graduate. It
has already been shown that education affects the relationship
between cognition and the pathological burden ofAD [48].While
themechanism for this phenomenon is not completely understood
the differences in the populations from which participants are
recruited should be taken into account as they could create
discrepancies in the observed results.
The second objective of this paper was to investigate the
effect of age on amyloid PET data fromwithin the large ADNI
population sample. The younger HCs had significantly less
amyloid deposition than the older HCs only in the putamen,
independently of their ApoE4 status, whereas no significant
differences in deposition were observed in the composite neo-
cortical region in younger or older HCs. The composite corti-
cal uptake values, however, for the younger HCs appeared to
be distinctly different for amyloid-positive and amyloid-
negative subjects. Conversely, probably due to the age-
related accumulation of amyloid [49], distribution in the older
HCs was more likely to be unimodal, shifted to the amyloid-
positive side, without any clear border between amyloid-
positive and amyloid-negative individuals.
Although most of the research investigating the role of age
in the amyloid load of AD patients has focused on EoAD
(onset at age <65 y) and LoAD (onset at age >65 y)
[23–25], we decided to investigate two groups of older pa-
tients in order to explore the effect of age on the amyloid load
in a more elderly population. In our study, age had an inde-
pendent effect on the amyloid load in diffuse cortical and
subcortical ROIs; amyloid deposition was lower in the older
AD patients than in the younger AD group (i.e., those aged
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<75 y). Differences between the age groups were also found in
the distribution of amyloid in the composite cortical regions in
AD patients. The distribution of amyloid in older patients was
more likely to be a mixture of two normal distributions, with a
clear distinction between amyloid-positive and amyloid-
negative patients, whereas the distribution in younger AD
patients was unimodal. When we investigated the true AD
groups (high amyloid uptake), age related differences between
groups were observed only in the putamen, where young AD
patients showed significantly lower amyloid deposition in
comparison to the older AD patients. This effect was observed
in all diagnostic groups (HC,MCI, AD), supporting an impor-
tant role of the striatum in the age-related accumulation of Aβ.
Although a large number of studies have investigated the
discriminative ability of amyloid imaging in individual co-
horts, no other study to our knowledge has been designed to
define and compare the additive value of amyloid imaging in
the assessment of patients across different age groups. The
results of this study illustrate the diminished sensitivity and
specificity of the Florbetapir cut-off point in an advanced el-
derly population in comparison to that in younger individuals,
when the clinical diagnosis was used as the gold standard, and
particularly the NINCDS-ARDRA criteria [27]. The high
number of amyloid-negative AD patients of advanced age in
the ADNI population, however, poses questions regarding the
diagnostic assessment of these patients, especially since recent
studies have shown that these individuals do not tend to dete-
riorate neuropsychologically [50], which probably indicates a
population of patients who have been misdiagnosed as having
typical AD. The amyloid-negative patients investigated here
were more likely to be ApoE4 non-carriers and on the whole
had inconclusive FDG-PET scans, due to diffuse non-specific
reductions in FDG uptake. Overall, in these patients, two bio-
markers and one genetic marker suggest that the cause of their
dementia is unlikely to be related to AD pathology and, con-
sequently, they might have been misdiagnosed. Conclusively,
the incorporation of amyloid PET into the clinical assessment
process could have led to reclassification of the amyloid-
negative demented patients, for instance, as suspected non-
amyloid-pathology dementia, which would have obvious ther-
apeutic implications. The effect of reclassification of clinically
diagnosed AD patients with the use of amyloid PET imaging
was found especially evident in the elderly patient population
(30% amyloid negative), where an additional 10 % of dement-
ed patients would benefit in comparison to the group aged
younger by an average of 10 years (20 % amyloid negative).
The independent positive effect of the ApoE4 allele on the
amyloid load was significant in both HC and AD patients in
every ROI except the hippocampus. This effect of ApoE4 on
the amyloid load in healthy individuals is in line with previous
publications [16, 51, 52]. Although the results in AD patients
differ from those in some published studies [53–55], they are
consistent with others [56, 57]. The lack of an ApoE4 effect in
the hippocampus could be associated with the paucity of neu-
ritic plaques in this area [1, 58–60], or the form of Aβ that can
be detected with the available PET amyloid tracers.
In summary, these results illustrate good correlation be-
tween two amyloid-specific radiotracers, Florbetapir and
PIB, in detecting Aβ deposition in unrelated, matched patient
populations. The results suggest that these tracers are compa-
rable, not only in the same participants but also across differ-
ent cohorts, where different population characteristics and
protocols apply. Nonetheless, the inherent characteristics of
the tracers vary substantially (non-specific WM binding,
range of GM values, discriminative ability of the two tracers),
limiting the interchangeable use of the tracers in multicentre
studies. Notwithstanding its limitations, this study also sug-
gests that the role of amyloid PET imaging becomes increas-
ingly important with increasing age in the diagnostic assess-
ment of clinically impaired patients. This finding could lead to
a dramatic decrease of the routine false AD diagnoses in very
old patients suffering from memory complaints with impor-
tant therapeutic implications.
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